Cytimmune Sciences
David Oarr has a diverse work experience spanning several industries. David worked at Cytimmune Sciences from 2016 to the present, first as a Consultant to the Board of Directors from February 2016 to January 2017, then as a Consultant to the Board and Corporate Officer from January 2017 to September 2019. Currently, they hold the position of President at Cytimmune Sciences.
Prior to their role at Cytimmune Sciences, David worked as an Independent Consultant at Communications, PR, and Marketing from March 2016 to September 2019. In this role, they provided services such as C-suite counseling, corporate communications and marketing, crisis management, brand building, media pitching, reputation management, fundraising, digital and social media marketing, and analytical research to a wide range of clients.
Before that, David held the position of Vice President at APCO Worldwide from August 1999 to February 2016.
During their early career, David worked as a Biochemist at the Henry M Jackson Foundation from August 1996 to July 1999. Their responsibilities included conducting HIV vaccine research, performing tasks such as peptide synthesis, DNA sequencing, cell culturing, immuno-assays, monoclonal antibody development, and analytical chemistry techniques. David also developed software for various scientific applications.
David Oarr received their high school diploma from Central High in 1991. David then pursued a Bachelor of Science degree in Molecular Biology and Biochemistry at the University of Maryland, where they studied from 1991 to 1996. After completing their undergraduate studies, David attended The Johns Hopkins University from 1998 to 2000, focusing on BioInformatics.
This person is not in any teams
This person is not in any offices
Cytimmune Sciences
CytImmune Sciences, Inc. created a first-in-class, patented nanomedicine platform, Aurimune™. All Aurimune products seek out and destroy the blood vessels inside any primary or metastatic solid tumor. Tumor blood vessel destruction alters the tumor microenvironment in a way that significantly improves the effectiveness of other therapies includingchemotherapies, radiation therapies and immunotherapies. CYT-6091, the first generation Aurimune nanomedicine and a first-in-class therapeutic, was shown to be safe and tumor-targeted in a Phase I Clinical Trial. CytImmune is raising funds to advance CYT-6091 through Clinical Trials. All Aurimune™ products are built around a 27nm gold nanoparticle core. Gold is known to be safe, has a flexible chemistry including forming covalent bonds, and can be manufactured with scale and precision in GMP conditions. All Aurimune products carry Tumor Necrosis Factor Alpha (TNF). Additionally, CytImmune developed a patented gold pegylation technology to prevent Aurimune removal by the immune system. This stealth attribute allows Aurimune to remain in circulation long enough to concentrate inside solid tumors. The Aurimune family of nanomedicines includes CYT-6091 and several second generation, multifunctional nanomedicines. Second generation nanomedicines use TNF to destroy tumor blood vessels, then deliver anti-cancer agents including chemotherapies and targeted biologics into the tumor. Preclinical data indicate this approach concentrates anti-cancer therapies inside solid tumors, which dramatically increases effectiveness while reducing drug-related side effects. Therapeutics delivered by second generation Aurimune products include:•Common Small Molecule Chemotherapies: Paclitaxel, Doxorubicin, Gemcitabine•Targeted Therapies and Biologics: TNF, Interferon Gamma, Mono and Bi-valent SMAC Memetics